Search

Displaying results 2151 - 2160 of 10000 in total
  1. Drug

    UCB-1184197

    go.drugbank.com/drugs/DB05092
    Investigational

    Sclerosis (MS). … (now UCB S.A.) and is a putative new drug for oral treatment of multiple sclerosis.

    Categories: Heterocyclic Compounds, 2-Ring
  2. Drug

    Cimicoxib

    go.drugbank.com/drugs/DB05095
    Investigational

    Cimicoxib is a selective COX-2 inhibitor being developed by Affectis as a treatment for depression and schizophrenia. … If approved, Cimicoxib would be the first drug in decades to treat depression by a new mechanism of action.

    Categories: Heterocyclic Compounds, 1-Ring, Selective Cyclooxygenase 2 Inhibitors (NSAIDs)
  3. Drug

    Pomaglumetad methionil

    go.drugbank.com/drugs/DB05096
    Investigational

    LY2140023 is an investigational drug from Lilly, which is being developed as a new treatment option for schizophrenia. … LY2140023 is an oral "prodrug," meaning it is devoid of intrinsic biological activity and, once administered, is metabolized to provide the active mGlu2/3 receptor agonist called LY404039.

  4. Drug

    Labetuzumab

    go.drugbank.com/drugs/DB05097
    Investigational

    Labetuzumab is a humanized monoclonal antibody to carcinoembryonic antigen that inhibits tumor growth. It is used in radioimmunotherapy.

  5. Drug

    AN-9

    go.drugbank.com/drugs/DB05103
    Investigational

    Pivaloyloxymethyl butyrate (AN-9), an acyloxyalkyl ester prodrug of butyric acid (BA), exhibited low toxicity and significant anticancer activity in vitro and in vivo.

    Synonyms: AN-9
  6. Drug

    Asimadoline

    go.drugbank.com/drugs/DB05104
    Investigational

    Asimadoline is an orally administered agent that acts as a kappa opioid receptor agonist. … Asimadoline is a proprietary small molecule therapeutic, originally discovered by Merck KGaA of Darmstadt, Germany. Asimadoline was originally developed to treat peripheral pain such as arthritis.

    Categories: Heterocyclic Compounds, 1-Ring
  7. Drug

    Fontolizumab

    go.drugbank.com/drugs/DB05111
    Investigational

    Fontolizumab (marketed under the trade name HuZAF™) is a humanized monoclonal antibody which is used as an immunosuppressive drug to treat Crohn's disease.

  8. Drug

    R1204

    go.drugbank.com/drugs/DB05118
    Experimental

    R1204 is G-protein-coupled receptor modulator. It is developed for the treatment of depression.

  9. Drug

    Rilapladib

    go.drugbank.com/drugs/DB05119
    Investigational

    It is a lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitor. Lp-PLA2 is an enzyme associated with the formation of atherosclerotic plaques. … Rilapladib is the third genomics-derived small molecule drug arising from the Human Genome Sciences-GlaxoSmithKline collaboration to enter clinical development.

    Categories: Heterocyclic Compounds, 1-Ring, Heterocyclic Compounds, 2-Ring
  10. Drug

    R1295

    go.drugbank.com/drugs/DB05122
    Experimental

    R1295 is an integrin antagonist currently in clinical trials for the treatment of rheumatoid arthritis. … Integrins are associated to the pathology seen in some of the autoimmune diseases such as rheumatoid arthritis.